Evidence map›Paper›PMID 41456951›Full record

ArticleCNS neuroscience & therapeutics2025

Transglutaminase-2 Promotes Microglial Synaptic Phagocytosis and Ameliorates Epileptic Seizures by Inhibiting ABCA1 Ubiquitination.

Zunlin Zhou, Xiujuan Wang, Juan Yang, Jiyao Qin, Bidan Feng, Qianqiong Qin, Jun Tian, Zhong Luo, Xiaoyan Yang, Hao Huang and 5 more

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zunlin ZhouDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Xiujuan WangDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Juan YangDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0003-4077-920X
Jiyao QinDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Bidan FengDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Qianqiong QinDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Jun TianDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Zhong LuoDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0002-7574-3293
Xiaoyan YangDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0002-3833-2460
Hao HuangDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0001-7739-275X
Xin XuDepartment of Neurology, Chongqing Key Laboratory of Neurology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0002-7216-3787
Juan LiDepartment of Neurology, Chongqing Key Laboratory of Neurology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zucai XuDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0002-6849-7928
Changyin YuDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0002-4529-9750
Haiqing ZhangDepartment of Neurology, Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province (ZSYS(2025)030), Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.ORCID 0000-0003-3935-7683

Funding

Chongqing Medical UniversityNational Natural Science Foundation of China 32160190National Natural Science Foundation of China 32460197National Natural Science Foundation of China 82171440Natural Science Foundation of Chongqing CSTB2024NSCQ-MSX0027the Science and Technology Project in guizhou Province zk[2025]-401
6 · The paper itself

Abstract

backgroundEpilepsy is a prevalent chronic neurological disorder characterized by its complex pathophysiology, with microglial phagocytosis being crucial for synaptic remodeling and epileptogenesis. Transglutaminase-2 (TGM2) holds a critical role in regulating microglial function and cognitive synaptic plasticity; however, the precise mechanisms by which TGM2 influences synaptic pruning and epileptogenesis remain unclear.

aimThis study aims to investigate the role of TGM2 in seizure susceptibility and its regulatory effects on microglial-mediated synaptic phagocytosis in a chronic epilepsy model. Accordingly, the following objectives were set: elucidate the fluorescent localization and protein expression characteristics of TGM2 in normal and epileptic brain tissues; analyze the impact of TGM2 on epileptic behavioral phenotypes; and investigate the molecular mechanisms underlying its regulation of microglial activation and synaptic phagocytic function using an epileptic mouse model.

methodsIn vivo experiments were performed using a kainic acid (KA)-induced chronic epilepsy mouse model established via intrahippocampal injection. Western blot and immunofluorescence analyses were employed to examine TGM2 expression and localization in the hippocampus of KA-treated mice. Adeno-associated virus vectors were used to achieve TGM2 overexpression or knockdown in the hippocampus, after which video-monitored behavioral assays and in vivo field potential recordings were used to evaluate seizure latency, frequency, and severity. Golgi-Cox staining, western blotting, and immunofluorescence were used to assess dendritic spine density in the hippocampal CA1 region, microglial polarization (M1/M2 phenotypes), and phagocytic activity. In vitro studies in BV2 microglia explored the molecular mechanisms of action of TGM2 using ubiquitination assays targeting ATP-binding cassette transporter A1 (ABCA1).

resultsTGM2 expression was significantly upregulated in the hippocampus of KA-induced epileptic mice, which prolonged the latency period to spontaneous recurrent seizures (SRS) and reduced SRS frequency. In contrast, TGM2 knockdown exacerbated seizure severity, which was characterized by a shortened latency period and increased SRS frequency. Golgi-Cox staining revealed that TGM2 overexpression decreased dendritic spine density in the CA1 region, whereas TGM2 knockdown had the opposite effect, indicating a role in synaptic remodeling. Functional analyses showed that TGM2 promoted microglial polarization toward an anti-inflammatory M2 phenotype, enhanced phagocytic activity, and upregulated the components of the complement system as well as the phagocytosis-related proteins. Conversely, TGM2 deficiency promoted the pro-inflammatory M1 phenotype, reduced phagocytic capacity, and downregulated the components of the complement system and the phagocytosis-related proteins. Mechanistically, TGM2 overexpression increased ABCA1 protein stability by inhibiting its ubiquitination, whereas TGM2 knockdown promoted ABCA1 ubiquitination and degradation. Immunofluorescence analysis revealed enhanced colocalization of TGM2 within the microglia.

conclusionThis study revealed that TGM2 suppresses epileptogenesis by enhancing microglial synaptic phagocytosis through the inhibition of ABCA1 ubiquitination, thereby regulating synaptic remodeling in the hippocampus. These findings establish a critical molecular link between TGM2-mediated microglial function and epileptogenesis, providing novel insights into therapeutic strategies targeting neuroinflammation and synaptic plasticity in epilepsy.

Indexed as

ATP Binding Cassette Transporter 1EpilepsyGTP-Binding ProteinsMicrogliaPhagocytosisSeizuresSynapsesTransglutaminasesUbiquitinationAnimalsDisease Models, AnimalHippocampusKainic AcidMaleMiceMice, Inbred C57BLAbca1 protein, mouseATP Binding Cassette Transporter 1GTP-Binding ProteinsKainic AcidProtein Glutamine gamma Glutamyltransferase 2Transglutaminases

Identifiers

PMID41456951
PMCPMC12745056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.